First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
José Manuel Ruiz Morales(Hospital Médica Sur), Daniel Yick Chin Heng(University of Calgary), J. Connor Wells(Queen's University), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Aristotelis Bamias(National and Kapodistrian University of Athens), James Brugarolas(The University of Texas Southwestern Medical Center), Toni K. Choueiri(Harvard University), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Sandhya Srinivas(Stanford Medicine), Jennifer J. Knox(National Cancer Center), Ulka N. Vaishampayan(University of Michigan), D. Scott Ernst, Lori Wood(Dalhousie University), Carmel Pezaro(Royal Marsden NHS Foundation Trust), Christian Kollmannsberger(BC Cancer Agency), Takeshi Yuasa(Japanese Foundation For Cancer Research), Reuben Broom(Auckland City Hospital), Jae‐Lyun Lee(Ulsan College), Brian I. Rini(Vanderbilt University Medical Center)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k